Management of hand osteoarthritis: from an US evidence-based medicine guideline to a European patient-centric approach

Nicholas Fuggle1 · Nathalie Bere2 · Olivier Bruyère3 · Mario Manuel Rosa4 · María Concepción Prieto Yerro5 · Elaine Dennison1 · Fitnat Dincer6 · Cem Gabay7 · Ida K. Haugen8 · Gabriel Herrero-Beaumont9 · Mickaël Hilligsmann10 · Marc C. Hochberg11 · Andrea Laslop12 · Radmila Matijevic13,14 · Emmanuel Maheu15 · Alberto Migliore16 · Jean-Pierre Pelletier17 · Régis Pierre Radermecker18 · François Rannou19 · Brigitte Uebelhart20 · Daniel Uebelhart21 · Nicola Veronese22 · Mila Vlaskovska23 · René Rizzoli20 · Ali Mobasheri3,24,25,26,27 · Cyrus Cooper1 · Jean-Yves Reginster3

Received: 13 March 2022 / Accepted: 8 June 2022 © Crown 2022

Abstract
Hand osteoarthritis is the most common joint condition and is associated with significant morbidity. It is of paramount importance that patients are thoroughly assessed and examined when complaining of hand stiffness, pain, deformity or disability and that the patient’s concerns and expectations are addressed by the healthcare professional. In 2019 the American College of Rheumatology and Arthritis Foundation (ACR/AF) produced guidelines which included recommendations for the treatment of hand osteoarthritis. An ESCEO expert working group (including patients) was convened and composed this paper with the aim to assess whether these guidelines were appropriate for the treatment of hand osteoarthritis therapy in Europe and whether they met with the ESCEO patient-centered approach. Indeed, patients are the key stakeholders in healthcare and eliciting the patient’s preference is vital in the context of an individual consultation but also for informing research and policy-making. The patients involved in this working group emphasised the often-neglected area of aesthetic changes in hand osteoarthritis, importance of developing pharmacological therapies which can alleviate pain and disability and the need of the freedom to choose which approach (out of pharmacological, surgical or non-pharmacological) they wished to pursue. Following robust appraisal, it was recommended that the ACR/AF guidelines were suitable for a European context (as described within the body of the manuscript) and it was emphasised that patient preferences are key to the success of individual consultations, future research and future policy-making.

Keywords Hand · Osteoarthritis · Management · Patient-centered · Treatment guideline

Introduction
Hand osteoarthritis is a highly prevalent disease [1] and is associated with substantial morbidity [2, 3]. It can be diagnosed radiographically or clinically with the percentage of radiographic osteoarthritis in the population ranging between 43% (from a global systematic review of patients aged 18–99 years) [4] to an age-standardized prevalence of 44% in females and 37% in males (aged 28–92 years) in the United States [1]. In Europe there are an estimated 748 million inhabitants [5] and the proportion of those aged over 60 years is set to rise [6]. Given osteoarthritis is strongly associated with ageing it is likely that the prevalence of hand osteoarthritis will grow [7]. However, it is important to note that osteoarthritis is a verified disease in its own right and not merely a sequela of a generic ageing process, and so requires specific diagnosis and management. Indeed, the management of hand osteoarthritis should be multi-modal including pharmacological and non-pharmacological approaches as documented in the recommendations from international learned bodies [8–10].

The American College of Rheumatology (ACR) and the Arthritis Foundation (AF) have recently published guidelines for the management of hand osteoarthritis [9]. In 2021 ESCEO (The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal
Diseases) convened an expert working group which comprised patients, clinicians, researchers, economists and regulators who performed reviews of the current literature relating to the management and patient preferences research in hand osteoarthritis. The primary aim of this group was to appraise (within the context of the current literature) whether these US guidelines were appropriate for a European context and to highlight the importance of a patient-centered approach to hand osteoarthritis management.

**Heterogeneity of hand osteoarthritis**

Hand osteoarthritis is an umbrella term under which sits an increasing number of clinical phenotypes [11]. Possible risk factors of the condition include; age-related, genetic, inflammatory (complement proteins, inflammmaging, innate immunity and systemic mediators) and metabolic (encompassing obesity and diabetes mellitus and possible cardiovascular associations) [12, 13].

These manifold causes are of paramount clinical importance when assessing a patient with hand pain. It is crucial to determine the types of symptoms, the onset of symptoms, the pattern of disease flares, extent of deformity (both soft tissue and bony enlargement) and the comorbid context of the condition, as these factors allow robust clinical decision-making with regard to diagnosis and management.

The clinical complaints which lead patients to approach healthcare services include pain, stiffness, loss of function, reduced quality of life, worries about the future and aesthetic concerns related to deformity [14]. The latter two of these are particularly prevalent in younger patients with osteoarthritis (especially women), and, radiographic assessment is highly informative to ascertain the trajectory of progression.

Hand radiographs are often used to confirm the diagnosis of hand osteoarthritis, to assess the degree of structural changes and to document the distribution of joint involvement. This latter point is particularly relevant given the different phenotypes of osteoarthritis affecting the interphalangeal joints or the thumb base joints [15]. The extent of damage for osteoarthritis can be graded as none, doubtful, definite, moderate and severe according to Kellgren and Lawrence radiographic scoring [16]. Erosive osteoarthritis is a particular phenotype which is characterised by central subchondral bone collapse and is associated with greater pain, a higher level of disability [3] and even an inflammatory element [17, 18]. Indeed, inflammatory osteoarthritis (which can occur independently of erosive osteoarthritis) is observed as increased grey scale synovitis on ultrasound (indicating synovial thickening and/or effusion) and even, occasionally, associated with increased synovial blood flow on power doppler examination [19]. Erosive osteoarthritis can be graded as normal, stationary, destructive or remodelling, according to the radiographic appearances [20].

After the clinical and/or radiographic examination has been performed, a management plan is then devised together with the patient once the patients’ preferences have been elicited.

**The opinion of patients**

The ESCEO expert working group included patients and their contribution provided novel insights into patient preferences and perspectives. They emphasised that hand osteoarthritis was a highly debilitating disorder with substantial impacts on function (“holding more than one kilogram was too heavy”), the common activities of daily living (“I was unable to turn a key”) and independence (“asking for help was very unpleasant”). They also experienced severe symptoms (“pain like hot oil on your skin”) which occurred with a clear cyclical pattern with inflammatory flares followed by relief and they also drew attention to the often-forgotten aesthetic concerns which arise due to finger deformations in hand osteoarthritis.

One of the patients described an encouraging response to celecoxib and chondroitin sulphate with, “a rapid response to medication”, however, she halted the celecoxib due to, “a fear of side effects” she had read about in the lay press. This emphasises how important it is to have open channels of communication between patients and clinicians to address these kinds of potential safety concerns and improve adherence.

Another patient had little response to pharmacological approaches and opted for surgical intervention and has been very satisfied with the result. This highlights the importance of communicating all available management options to patients as their disease progresses.

All patients agreed that pharmacological therapies should focus on alleviating pain and dysfunction and be combined with a beneficial safety profile. In some healthcare systems economic considerations are also taken into account including costs of medication and non-pharmacological therapies (such as rehabilitation and physical therapy), particularly if the patient is funding their own care.

With regard to intra-articular therapies (including hyaluronic acid and corticosteroids), all patients agreed that the size of the needle and volume of injection should be minimised, and the interval between injections should be as long as possible.

Conversations around these topics (specific symptoms for the patient, pharmacological/surgical intervention, the desired outcomes of an intervention, tolerability of intra-articular therapy for the individual patient) should be a mainstay when eliciting patient preferences.
Patient preferences and shared decision-making

ESCEO is a patient-centered organisation which aims to promote the use of patient perspectives in research and intervention development, policy-making and to ensure that patients are encouraged to take an active role in the clinical decision-making surrounding their individual care [21].

When it comes to deciding on a course of management in a clinical setting, the clinician’s choice and the patient’s choice intersect at the point at which a partnership is formed through shared decision-making. This is vital in order to elicit the patients’ preferences.

Patient preferences, with regard to medications, have been defined as “a mental process that patients use to compare and choose one drug over another by comparing the good and bad” [22]. These preferences are vital to decision-making for an individual in a clinical setting, but also a population at a policy level.

In the clinical setting, patient preferences help healthcare professionals to tailor the management plan at the patient level, to facilitate true, shared decision-making and to improve patient ‘buy-in’ and adherence to therapy.

At a policy level, patients should play a key role in the design of healthcare interventions and models of care, the population level assessment of risk-benefit (from a regulatory perspective) and the assessment of the value of an intervention (from a reimbursement perspective).

Methods to elicit preferences have been devised in the discipline of health economics and include ‘revealed’ preferences and ‘stated’ preferences. Revealed preferences are observed by recording consumer choice in a free market, however, this is difficult and impractical in a healthcare setting where ‘choice’ may be influenced by local prescribing behaviours, clinician preference and the level of evidence of a therapy.

Stated preferences are based on hypothetical choices and can be established via exploration (in focus groups or structured interviews) or via elicitation using a discrete choice experiment (DCE). A DCE is a tool which decomposes a product into its constituent ‘attributes’ (or characteristics) which are then placed before a group of patients/consumers in the form of a number of discrete (often binary) choices. Statistical analyses are used to produce an economic model which calculates the attributes that are most important to the patients/consumers. The product can then be developed with these preferences in mind.

DCEs have been utilised in an attempt to elicit patient preferences for the management of osteoarthritis. A previous ESCEO DCE of patients with hip and knee osteoarthritis showed that the most important treatment attributes were impact on disease progression followed by the ability to improve walking and reduce pain [23]. In another US DCE study, including hip and knee osteoarthritis patients, healthcare providers and insurance company employees, the most important attribute was out of pocket costs [24] (though it should be noted that this was not included as an attribute in the ESCEO study and might be related to the US healthcare distribution system). Another DCE in the US included patients with osteoarthritis and chronic low back pain and found a preference for daily oral medication over longer term intravenous therapy [25]. The only DCE in hand osteoarthritis was directly related to the question of preference for arthroplasty versus arthrodesis as a surgical intervention and found that post-operative stiffness, grip strength, cost and need for future surgical procedures were all important attributes [26]. Indeed, the only attribute which was not important was ‘recovery time’ and this may have been because the choice was only between 10 weeks or 12 weeks. Despite the lack of specific hand osteoarthritis DCEs, it is possible to see that this tool could be used to create a holistic impression of patient preferences for therapies in this disease area and should be the subject of future research.

In summary, there is an increasing emphasis on patient-centered research (outcome assessment tools, expectations and therapeutic management) and it is therefore vital to engage patients in identifying current research needs, the design and conduct of clinical studies and subsequent regulatory assessment [21]. They should also be consulted on post-marketing safety surveillance and efficacy data collection and, if applicable, be represented in the learned bodies devising practice guidelines. Indeed, patient preferences should be incorporated throughout the medicinal (and non-pharmacological) product life cycle [27].

It is not enough for patients to sit on panels. They should also be trained and educated to enable them to engage in the most comprehensive way possible and offer insights on the most complex elements of clinical science. Capturing patient perspectives is a highly active process and should incorporate multiple approaches to engagement [28].

Thus, in managing hand osteoarthritis in the clinic, in drawing up a research road map and informing policy for hand osteoarthritis we must involve the patient as the key stakeholder. This will lead to better adoption of interventions, better patient satisfaction and better therapeutic adherence.

Management of hand osteoarthritis: the ACR/AF 2019 guidelines

In 2019, ESCEO published a treatment algorithm for the management of knee osteoarthritis [29] which has been endorsed beyond Europe in other continents [30, 31].
Although this is not specific to hand osteoarthritis, the key messages and progression through therapies can be transferred as a guide to use in osteoarthritis of the hand. Other European recommendations for the management of hand osteoarthritis have been published, but without a patient-centered focus or algorithm for therapeutic escalation [32]. In 2019, the ACR and AF published evidence-based recommendations for the management of hand osteoarthritis, which may be used to inform practice in Europe [9].

In this guideline, hand osteoarthritis is defined according to ACR classification criteria [33]. These include the presence of hand symptoms (limited to pain, aching, stiffness) and the findings of clinical examination [33]. Three key features are elicited from specific examination of the distal and proximal interphalangeal joints of the 2nd and 3rd fingers and the trapezio-metacarpal joints of both hands (10 joints). These features include: hard tissue enlargement of ≥2 of these ten joints or ≥2 distal interphalangeal joints or deformity of ≥1 of these joints. In addition to the above, there must be fewer than three swollen metacarpophalangeal joints. If three or four of the above features (in addition to the presence of hand symptoms) are identified then this confers a clinical diagnosis of hand osteoarthritis.

The authors of the ACR/AF 2019 recommendations [9] used a robust methodology in which a core committee of 5 experts honed the scope of the literature review with regard to population, indication, comparator group and outcomes (PICO). The outcomes were defined as improvement in pain and improvement in function. Literature searches were performed up to and including August 2018 and a meta-analysis was performed for the collated papers.

A wider community of experts, including patient representatives, then voted on the evidence for each hand osteoarthritis intervention, and graded them as either a ‘strong’ or ‘conditional’ recommendation ‘for’ or ‘against’ the intervention. A patient panel was also formed as part of the guideline formulating team.

A recommendation was described as ‘strong’ if greater than or equal to 70% of the constitutive committee voted either for or against the use of the intervention and a ‘conditional’ recommendation was made if 50–70% of the committee voted for or against the intervention.

A strong recommendation ‘for’ an intervention meant that patients should receive the intervention for hand osteoarthritis, a strong recommendation ‘against’ an intervention meant that patients should not receive the intervention for hand osteoarthritis. A conditional recommendation meant that a process of shared decision-making (between patient and clinician) should be used to decide if the patient was to receive the intervention.

Interventions were grouped into two categories ‘physical, psychosocial and mind-body’ (avoiding the term ‘non-pharmacological’) and ‘pharmacological’. In the first of these, strong recommendations were made for the use of self-efficacy programmes, self-management programmes and 1st carpo-metacarpal joint orthoses. Conditional recommendations were made for the use of cognitive behavioural therapy, acupuncture (complementary medicine), heat therapies (including paraffin wax baths) and orthoses for the interphalangeal joints.

For pharmacological agents, a strong recommendation was made for oral non-steroidal anti-inflammatory drugs (NSAIDs) and conditional recommendations for topical NSAIDs, intra- articular injections of glucocorticoid, chondroitin sulphate, paracetamol, duloxetine and tramadol (the latter three inferred from knee osteoarthritis studies, in the absence of hand osteoarthritis-specific literature).

Strong recommendations were made against the use of glucosamine (hydrochloride and sulphate), hydroxychloroquine, methotrexate, anti-TNF and IL-1 inhibitors. Conditional recommendations were made against intra-articular injection of hyaluronic acid and the use of topical capsaicin.

In light of these guidelines we will document some of the key evidence for pharmacological therapies in hand osteoarthritis and highlight the non-pharmacological recommendations from the ACR/AF 2019 guidelines. This is followed by a summary of potential novel interventions for hand osteoarthritis.

**NSAIDs and COX-2 inhibitors**

These medications have been in usage for the treatment of osteoarthritis for decades and their efficacy (in osteoarthritis though perhaps not hand-specific disease) and safety profiles are well-established (with documented adverse effects including GI complications, cardiovascular events, renal impairment and hypersensitivity, headaches, dizziness, rarely hepatotoxicity, drug interactions) [34].

Non-selective NSAIDs are well known to be associated with upper gastrointestinal, renal and cardiovascular adverse effects. A large meta-analysis demonstrated that the relative risk (RR) of upper gastrointestinal adverse events with naproxen (RR 4.22 (95% CI 2.71, 6.56)) was marginally (numerically) higher than ibuprofen (RR 3.97 (95% CI 2.22, 7.10)) and substantially higher than diclofenac (RR 1.89 (95% CI 1.16, 3.09)) [35]. The use of a proton pump inhibitor contemporaneously to NSAIDs reduces the risk of upper GI adverse events to the same level as a COX-2 selective formulation [36].

Cardiovascular adverse effects of NSAIDs have been the subject of extensive investigation with a comparison of agents showing that a significantly increased risk is observed with naproxen (RR 1.87 (95% CI 1.10, 3.16)) and diclofenac (RR 1.85 (95% CI 1.77, 2.94)) but not with ibuprofen (RR 1.44 (95% CI 0.89, 2.33)) [35]. A more
recent meta-analysis included 26 randomised controlled trials of non-selective NSAIDs and COX-2 inhibitors which provides a granular assessment of cardiovascular risk and showed that rofecoxib was the only agent with an increased odds of myocardial infarction (OR 1.81 (1.38, 2.38)) and composite cardiovascular risk score (OR 1.6 (95% CI 1.31, 1.98)) [37]. Celecoxib was associated with reduced odds of stroke and cardiovascular adverse events (though there was substantial heterogeneity in the doses of celecoxib used in the meta-analysis) [37]. This was supported by the safety outcomes of the PRECISION trial which demonstrated that celecoxib was non-inferior to both ibuprofen and naproxen in terms of cardiovascular risk [38]. Cardiovascular and gastro-intestinal risks seem to increase with age, but recent data did not show an age-related increase of the RR. Rather, it seems that there is an age-related increase of the absolute risk, multiplied by around 2 for either CV or GI risks between 70–79 and ≥ 80 years old [34]. Patients should be counselled using this information prior to prescription.

Analyses performed by an ESCEO working group investigated the adverse effect profiles of pharmaceutical interventions in osteoarthritis. For COX-2 inhibitors, meta-analyses showed marginally increased risks of abdominal pain (Relative Risk (RR) 1.40 (95% CI 1.08, 1.80)), hypertension (RR 1.45 (95% CI 1.01, 2.10), rofecoxib only), peripheral oedema (RR 1.61 (95% CI 1.09, 2.40)) and generalised oedema (RR 1.91 (95% CI 1.08, 3.39)) compared to placebo [39].

Topical agents were associated with an increased risk of any adverse event (RR 1.16 (95% CI 1.04, 1.29)) and withdrawal due to an adverse effect (RR 1.49 (95% CI 1.15, 1.92)) (which was largely driven by the effect of topical diclofenac) [40], but the risk of serious adverse events was not significantly increased (RR 0.79, (95% CI 0.37, 1.71)).

Although the above studies did not focus specifically on hand osteoarthritis, they do depict the therapeutic and safety landscape of non-selective and selective NSAIDs in osteoarthritis in general and justify their inclusion as strong recommendations in the ACR/AF 2019 guidelines [9].

### Oral paracetamol

Paracetamol, which was only conditionally recommended in the ACR/AF 2019 guidelines [9], provides an analgesic benefit (standard mean difference of pain score between treatment versus placebo group) of 0.14 (95% CI 0.05, 0.22) in knee osteoarthritis [41, 42], though the overall mortality relative risk is 1.28 (95% CI 1.26, 1.30) [43]. Based on these data the true risk of paracetamol may well be higher than currently perceived in the clinical community and, thus, paracetamol should only be used for short-term relief, if at all.

### SYSADOAs

The Symptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOAs) include glucosamine sulphate, chondroitin sulphate and diacerein which aim to alleviate symptoms and elicit functional improvement [44–46]. Meta-analyses have demonstrated small to moderate benefit for prescription-grade crystalline glucosamine sulphate, chondroitin sulphate and diacerein in osteoarthritis it general [44, 47–49] and a 2019 meta-analyses of safety found no substantial adverse effects from this class of medications [50].

Hand-specific osteoarthritis studies include a retrospective, observational study of glucosamine sulphate in 108 participants which demonstrated a significant reduction in pain visual-analogue score and Functional Index of Hand Osteoarthritis (FIHOA) score against control at both 3 and 6 months of follow-up [51]. Contrary to this demonstration of symptomatic benefit, a randomised controlled trial of diacerein in 86 participants in 2013 showed no change in hand pain as measured by the Australian/Canadian hand index (AUSCAN) pain score, though this was only over 4 weeks of follow-up [52].

The role that these agents play in the treatment of osteoarthritis differs between learned bodies with ESCEO recommending pharmaceutical-grade glucosamine sulphate and/or chondroitin sulphate as first-line background treatments but OARSI strongly recommending against their use in hip and knee osteoarthritis [53]. In the ACR/AF 2019 guideline, chondroitin sulphate is conditionally recommended for the treatment of hand osteoarthritis (the conditional nature of this recommendation being due to the small evidence base) [9] which aligns with the EULAR recommendations from 2018 [32].

Chondroitin sulphate is a complex sugar found in the cartilage of some animals and fish and is taken as dietary supplement in order to stimulate cartilage repair and reduce cartilage degradation. There are data to support the use of chondroitin sulphate in osteoarthritis [46] (including beneficial effects on symptoms of up to 3 months [54]) but fewer relating specifically to hand osteoarthritis. Structural improvements including reduced structural damage and reduced occurrence of erosive hand osteoarthritis have previously been demonstrated [55].

Gabay and colleagues performed a well-powered, randomised controlled trial of chondroitin sulphate which included 162 participants (80 chondroitin sulphate and 82 placebo) and 6 months of follow-up. For the primary outcomes there was an approximately 20 mm reduction in visual analogue score for pain, a reduction in FIHOA score (of approximately 3 units, where 30 is the worst possible score) and (for secondary outcomes) a reduction in the duration of early morning stiffness (by approximately
5 min) for those treated with chondroitin sulphate compared to the placebo group [56]. Although no effect was observed on grip strength, rescue paracetamol usage or safety, the symptomatic benefit of chondroitin sulphate, combined with good tolerance, justify its inclusion in the ACR/AF guideline[9] as a conditional recommendation for hand osteoarthritis.

It is recognised, from a scoping review by Honvo and colleagues [57] on the role of collagen derivatives in osteoarthritis, that further research is needed to make definitive conclusions regarding the role of SYSADOAs in the treatment of osteoarthritis as a whole and hand osteoarthritis as a specific case.

**Intra-articular injections**

In the 2019 ACR/AF guideline for osteoarthritis management [9], intra-articular injection with corticosteroid is conditionally recommended and injection with hyaluronic acid is conditionally recommended against.

For the corticosteroid injection recommendation it is important to recognise that the EULAR 2018 guidance [8] is similar in stating that injection can be considered specifically for those with painful interphalangeal joints (through the ACR/AF guidance [9] provides no specific recommendation for the anatomical location (interphalangeal or carpo-metacarpal) which can be injected).

In the EULAR 2018 guideline[8] it is not recommended to inject the base of the thumb with steroid (hyaluronic acid is not addressed) in hand osteoarthritis, likely based on findings (such as that of Kroon and colleagues[32]) of no clear benefit of corticosteroid or hyaluronic thumb base injections.

However, intra-articular, base of thumb injections of hyaluronic acid [58, 59] (for chronic management) and corticosteroid [59–61] (for acute phase management) appear to be promising approaches and could be conditionally proposed (though with the caveat that further efficacy and safety data are required).

**Physical, psychosocial and mind–body approaches**

There are a host of non-pharmacological interventions considered for hand osteoarthritis. Exercise is strongly recommended with a focus on overcoming “barriers to participation” by addressing “patient preference and access” (access referring to the affordability and transportation to attend the given exercise intervention [9]. Weight loss is strongly recommended for hip and knee osteoarthritis but not for hand osteoarthritis) [9]. The recommendation for exercise in hand osteoarthritis is supported by a Cochrane review from 2017 which stated benefits such as reduced pain and stiffness [62]. However, the type of exercise to perform, the duration, number and rhythm of sessions need to be precisely specified to patients who frequently ask for this kind of information. Interventions which are recommended for ‘consideration’ in the management of hand osteoarthritis in the ACR/AF 2019 guideline include orthoses (particularly for thumb base OA, but also including digital orthoses, ring splints), cognitive behavioural therapy, thermal interventions, paraffin baths, kinesiotaping for the 1st CMC joint and acupuncture [9]. Iontophoresis is conditionally recommended against for patients with 1st CMC osteoarthritis due to an absence of randomised controlled trials [9].

The gut microbiome is an area of interest with regard to osteoarthritis symptoms and it is clear that alterations in gut microbiota are associated with osteoarthritis and can alter drug metabolism and bioavailability [63]. Nutritional interventional studies support a potential contribution of the gut microbiome to osteoarthritis in both animal models and human subjects [63].

It is also worth considering and treating concurrent conditions including fibromyalgia which have a substantial prevalence in patients with osteoarthritis [64].

**Novel therapeutic options**

There are a number of therapeutic approaches being evaluated or developed for the treatment of hand osteoarthritis. Indeed, at the time of writing, there are 87 studies of hand osteoarthritis on clinicaltrials.gov including 15 ongoing trials of agents such as methotrexate, colchicine and cannabinoids.

A total of 16 non-pharmacological interventions have been trialled including exercise, orthoses, education, mud packs and transcutaneous auricular vagus nerve stimulation. Studied pharmacological agents included topical therapies, SYSADOAs, cannabinoids, pregabalin, apremilast and biologic agents including denosumab, tocilizumab and adalimumab.

Trials of biologic agents have shown no significant benefit to date, including: lutikizumab [65], etanercept [66], ultilimab [67], adalimumab [68, 69], tocilizumab [70]. Benefit is yet to be demonstrated for hydroxychloroquine [71–73], colchicine [74] or methotrexate [75] and the recent published trials do not advocate in favour of the use of these drugs.

Oral steroid does appear to provide some benefit for flares of hand osteoarthritis, as observed in the Hand Osteoarthritis Prednisolone Efficacy (HOPE) trial [76]. This was a double-blind, placebo-controlled trial of 10 mg oral prednisolone across two sites in the Netherlands, focused on hand osteoarthritis patients with evidence of active inflammation at the interphalangeal joints. Six weeks of prednisolone (with
a 2-week tapering period) led to a reduction in finger pain visual analogue score with a mean between-group difference (for prednisolone vs placebo) of -16.5 (95% CI -26.1, − 6.9, p = 0.0007) (in favour of prednisolone) observed, suggesting a role for a short course of oral prednisolone in treatment of osteoarthritis flares.

GCSB-5, a mixture of 6 herbal extracts, has shown promise in a Korean study which demonstrated some symptomatic benefit in hand osteoarthritis at 4 weeks (sustained to 16 weeks) with a reduction of AUSCAN pain score greater than that seen with placebo (-9.0 (95% CI -23.8, -0.4) vs -2.2 (95% CI -16.7, 6.0), p = 0.01) [77]. There is a relative paucity of literature relating to the potential benefits of alternative therapies (including ginger, curcumin, protein-rich plasma) for osteoarthritis and further high quality research is required [78].

**Conclusion**

Hand osteoarthritis is a distinct disease rather than simply a sequela of aging which requires multimodal management in the form of non-pharmacological and pharmacological approaches. Through the review and analysis of this ESCEO working group it is clear that the ACR/AF 2019 guidelines for hand osteoarthritis followed a robust methodology and are formally endorsed by ESCEO for usage for the management of European patients.

ESCEO agrees that, within the SYSADOAs family, chondroitin sulphate is the only agent which has successfully demonstrated efficacy for pain and function (in this particular indication). This evidence of efficacy is complemented by good tolerance and therefore justifies that the positive recommendation from the ACR/AF is applied to the European population. It would, nevertheless, be interesting to see further trials confirming the study by Gabay and colleagues [56] (despite the fact that this study was conducted with a robust methodology and an independent statistical analysis of the outcomes).

The ESCEO guidelines are written using a patient-centric approach and in this particular case, we received two fascinating case-studies from patients who highlighted the patient experience and patient preference. The main point that should be reemphasized is that both patients described hand osteoarthritis as a truly disabling disorder. One of them was very happy with the therapeutic approaches that were offered to her (chondroitin sulphate and Celecoxib) but her Celecoxib therapy was interrupted due to concerns (born of the lay press) regarding the possible cardiovascular adverse effects of coxibs. This highlights that it is immensely important to facilitate proper communication between physicians and patients, since these putative adverse effects have not been confirmed for celecoxib. She clearly expressed a cyclical pattern of pain with periods of inflammation (flares) followed by periods of relief. She also experimented with alternative medicines some of which had had a positive effect.

The second patient also described the serious impact of hand osteoarthritis on her daily life. As opposed to the first patient, she was not content with the pharmacological approaches that were offered to her and decided to pursue surgical intervention (proximal interphalangeal prosthesis). Despite the significant financial implication, she is very satisfied with the surgical outcome.

Both patients insisted that pharmacological approaches should provide alleviation for pain and disability, and should be associated with a good safety profile. They highlighted the fact that they might be prepared to consider paying a financial premium, providing that the medication (or the surgical treatment) was effective. Regarding intra-articular hyaluronic acid or steroid injections, they emphasised that they need to see some proof of efficacy and that they would prefer devices using a small needle, minimal volume of injection and, if possible, as few injections as possible.

Patient preference research and the derived health economics analyses support the use of a pharmacological management of hand osteoarthritis. Corticosteroid injections appear to be a promising approach in the acute phase of the disease with hyaluronic acid for chronic symptoms but both require further demonstrations of efficacy and safety. This is also the case for several medications (including glucosamine sulphate) which were or are currently undergoing investigation. Biologic agents have shown no significant benefit, to date.

In conclusion, this paper describes a patient-centered approach to hand osteoarthritis care and highlights the endorsement of the ACR/AF 2019 hand osteoarthritis guidelines for usage in European patients.

**Acknowledgements** The authors would like to express particular gratitude to the patients who took part in this ESCEO working group. Their contribution was invaluable to this article.

**Author contributions** All authors contributed to the review conception and design. All authors read and approved the final manuscript.

**Funding** The ESCEO Working Group was funded by the ESCEO. The ESCEO receives unrestricted educational grants to support its educational and scientific activities from non-governmental organizations, not-for-profit organizations, non-commercial or corporate partners. The choice of topics, participants, content and agenda of the Working Groups as well as the writing, editing, submission and reviewing of the manuscript are the sole responsibility of the ESCEO, without any influence from third parties.

**Declarations**

**Conflict of interest** NB, MCSR, MCPY, FD, CG, GHB, MCH, AL, RM, AM, JPP, RPR, FR, BU, DU, MV, RR, AM and CC report no
conflict of interest. OB reports consulting or lecture fees for Amgen, Apteissin, Biophytis, IBSA, MEDA, Mylan, Novartis, Sanofi, Servier, SMB, TRB Chemedica, UCB, Viatris. EMD reports support from Pfizer, UCB, Lilly and Viatris. NF reports educational grants from Pfizer and Eli Lilly. IKH reports consultancies for Novartis and Abbvie, research grant from Pfizer (paid to institution), all outside of the submitted work. MH reports research grant through institution from Amgen, Radius Health, ViV Healthcare, BD; lecture fees from Teva and Mylan Pharmaceuticals and consulting fees from UCB. EM reports consultancy or speaking fees for Abiogen, Expanscience, Fidia, Meda-Mylan, Pierre Fabre Labs, Sublimed, TRB Chemedica. JYR reports consulting fees or advisory board participation for IBSA-Genevier, Mylan, Radius Health and Pierre Fabre, lecturing fees for IBSA-Genevier, Mylan, Cnial and Dairy Research Council (DRC) and grant support from IBSA-Genevier, Mylan, Cnied and Radius Health. NV reports participation in advisory boards for Mylan, Fidia, Sanofi-Aventis, Viatris, IBSA.

Human and animal rights This article is a retrospective review. To the authors’ knowledge, the reviewed studies were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent For this retrospective review, formal consent is not required.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Haugen IK, Englund M, Aliabadi P et al (2011) Prevalence, incidence and progression of hand osteoarthritis in the general population: the Framingham Osteoarthritis Study. Ann Rheum Dis 70:1581–1586. https://doi.org/10.1136/ard.2011.150078
2. Kwok WY, Kloppenburg M, Marshall M et al (2013) Comparison of clinical burden between patients with erosive hand osteoarthritis and inflammatory arthritis in symptomatic community-dwelling adults: the Keele clinical assessment studies. Rheumatology (Oxford). 52:2260–2267. https://doi.org/10.1093/rheumatology/ket267
3. Kwok WY, Kloppenburg M, Rosendaal FR et al (2011) Erosive hand osteoarthritis: its prevalence and clinical impact in the general population and symptomatic hand osteoarthritis. Ann Rheum Dis 70:1238–1242. https://doi.org/10.1136/ard.2010.143016
4. Pereira D, Peleteiro B, Araújo J et al (2011) The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthritis Cartilage 19:1270–1285. https://doi.org/10.1016/j.joca.2011.08.009
5. Worldometer (2021). https://www.worldometers.info. Accessed Jan 2022
6. United Nations WB. Population projections (2022). https://data.worldbank.org/indicator/SP.POP.GROW. Accessed Jan 2022
7. Turkiewicz A, Petersson IF, Björk J et al (2014) Current and future impact of osteoarthritis on health care: a population-based study with projections to year 2032. Osteoarthritis Cartilage 22:1826–1832. https://doi.org/10.1016/j.joca.2014.07.015
8. Kloppenburg M, Kroon FP, Blanco FJ et al (2019) 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis 78:16–24. https://doi.org/10.1136/annrheumdis-2018-213826
9. Kolasinski SL, Neogi T, Hochberg MC et al (2020) 2019 American college of rheumatology/arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 72:149–162. https://doi.org/10.1002/acr.24131
10. Bannuru RR, Osani MC, Vaysbrot EE et al (2019) OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 27:1578–1589. https://doi.org/10.1016/j.joca.2019.06.011
11. Marshall M, Watt FE, Vincent TL et al (2018) Hand osteoarthritis: clinical phenotypes, molecular mechanisms and disease management. Nat Rev Rheumatol 14:641–656. https://doi.org/10.1038/s41584-018-0095-4
12. Mobasher A, Batt M (2016) An update on the pathophysiology of osteoarthritis. Ann Phys Rehabil Med 59:333–339. https://doi.org/10.1016/j.rehab.2016.07.004
13. Courtays A, Sellam J, Maheu E et al (2017) Coronary heart disease is associated with a worse clinical outcome of hand osteoarthritis: a cross-sectional and longitudinal study. RMD Open 3:e000344. https://doi.org/10.1136/rmdopen-2016-000344
14. Hodkinson B, Maheu E, Michon M et al (2012) Assessment and determinants of aesthetic discomfort in hand osteoarthritis. Ann Rheum Dis 71:45–49. https://doi.org/10.1136/ard.2011.153965
15. Deveza LA, Nelson AE, Loeser RF (2019) Phenotypes of osteoarthritis: current state and future implications. Clin Exp Rheumatol 37:64–72
16. Kellgren JH, Lawrence JS (1957) Radiological assessment of osteo-arthritis. Ann Rheum Dis 16:494–502. https://doi.org/10.1136/ard.16.4.494
17. Haugen IK, Mathiassen A, Slatkowsky-Christensen B et al (2016) Synovitis and radiographic progression in non-erosive and erosive hand osteoarthritis: is erosive hand osteoarthritis a separate inflammatory phenotype? Osteoarthritis Cartilage. 24:647–654. https://doi.org/10.1016/j.joca.2015.11.014
18. Wittoek R, Cruyssen BV, Verbruggen G (2012) Predictors of functional impairment and pain in erosive osteoarthritis of the interphalangeal joints: comparison with controlled inflammatory arthritis. Arthritis Rheum 64:1430–1436. https://doi.org/10.1002/art.33502
19. Keen HJ, Lavie F, Wakefield RJ et al (2008) The development of a preliminary ultrasonographic scoring system for features of hand osteoarthritis. Ann Rheum Dis 67:651–655. https://doi.org/10.1136/ard.2007.077081
20. Kaufmann RA, Lögters TT, Verbruggen G et al (2010) Osteoarthritis of the distal interphalangeal joint. J Hand Surg 35:2117–2125. https://doi.org/10.1016/j.jhsa.2010.09.003
21. de Wit M, Cooper C, Tugwell P et al (2019) Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res 31:905–915. https://doi.org/10.1007/s40520-019-01193-8
22. PREFER. Patient preferences (Innovative Medicines Initiative). https://www.imi-prefer.eu/. Accessed Jan 2022
23. Hiligsmann M, Dennison E, Beaudart C et al (2020) A discrete-choice experiment to assess patients’ preferences for osteoarthritis treatment: an ESCEO working group. Semin Arthritis Rheum 50:859–866. https://doi.org/10.1016/j.semarthrit.2020.08.005

24. Arslan IG, Huls SPI, de Bekker-Grob EW et al (2020) Patients’, healthcare providers’, and insurance company employees’ preferences for knee and hip osteoarthritis care: a discrete choice experiment. Osteoarthritis Cartilage 28:1316–1324. https://doi.org/10.1016/j.joca.2020.07.002

25. Turk D, Boeri M, Abraham L et al (2020) Patient preferences for osteoarthritis pain and chronic low back pain treatments in the United States: a discrete-choice experiment. Osteoarthritis Cartilage 28:1202–1213. https://doi.org/10.1016/j.joca.2020.06.006

26. Harris CA, Shauver MJ, Yuan F et al (2018) Understanding patient preferences in proximal interphalangeal joint surgery for osteoarthritis: a conjoint analysis. J Hand Surg Am 43:615-624.e614. https://doi.org/10.1016/j.jhsa.2018.03.001

27. van Overbeeke E, Janssens R, Whichello C et al (2019) Design, conduct, and use of patient preference studies in the medical product life cycle: a multi-method study. Front Pharmacol. https://doi.org/10.3389/fphar.2019.01395

28. de Wit M, Cooper C, Reginster JY (2019) Practical guidance for patient-centred health research. Lancet 393:1095–1096. https://doi.org/10.1016/S0140-6736(19)30034-0

29. Bruyère O, Honvo G, Veronese N et al (2019) An updated algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint. Aging Clin Exp Res 33:1149–1156. https://doi.org/10.1007/s40266-019-00661-0

30. Zhang Z, Huang C, Cao Y et al (2021) revised algorithm for the management of knee osteoarthritis—the Chinese viewpoint. Aging Clin Exp Res 33:2141–2147. https://doi.org/10.1007/s40520-021-01906-y

31. Yeap SS, Tanavalee A, Perez EC et al (2021) 2019 revised algo- rithm for the management of knee osteoarthritis: the Southeast Asian viewpoint. Aging Clin Exp Res 33:1149–1156. https://doi.org/10.1007/s40520-021-01834-x

32. Kroon FPB, Carmona L, Schoones JW et al (2018) Efficacy and safety of non-pharmacological, pharmacological and surgical treatment for hand osteoarthritis: a systematic literature review informing the 2018 update of the EULAR recommendations for the management of hand osteoarthritis. RMD Open. 4:e000734. https://doi.org/10.1136/rmdopen-2018-000734

33. Altman R, Alarcón G, Appelrouth D et al (1990) The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 33:1601–1610. https://doi.org/10.1002/art.1780331101

34. Cadet C, Maheu E (2021) Non-steroidal anti-inflammatory drugs in the pharmacological management of osteoarthritis in the very old: prescribe or proscribe? Ther Adv Musculoskelet Dis. https://doi.org/10.1177/17597720211022149

35. Bhala N, Emberson J, Merhi A et al (2013) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382:769–779. https://doi.org/10.1016/s0140-6736(13)60900-9

36. Wang X, Tian HJ, Yang HK et al (2011) Meta-analysis: cycloox- ygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Eur J Gastroenol Hepatol 23:876–880. https://doi.org/10.1097/MEG.0b013e328349de81

37. Gunter BR, Butler KA, Wallace RL et al (2017) Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis. J Clin Pharm Ther 42:27–38. https://doi.org/10.1111/jcpt.12484

38. Nissen SE, Yeomans ND, Solomon DH et al (2016) Cardiovascu- lar safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 375:2519–2529. https://doi.org/10.1056/NEJMoa1611593

39. Curtis E, Fuggle N, Shaw S et al (2019) Safety of cycloxy- genase-2 inhibitors in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging 36:25–44. https://doi.org/10.1007/s40266-019-00664-x

40. Honvo G, Leclercq V, Geerinck A et al (2019) Safety of topical non-steroidal anti-inflammatory drugs in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging 36:45–64. https://doi.org/10.1007/s40266-019-00661-0

41. Zhang W, Jones A, Doherty M (2004) Does paracetamol (acetam- inophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 63:901–907. https://doi.org/10.1136/ard.2003.018531

42. Zhang W, Nuki G, Moskowitz RW et al (2010) OARSI recommenda- tions for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 18:476–499. https://doi.org/10.1016/j.joca.2010.01.013

43. Roberts E, Delgado Nunes V, Buckner S et al (2016) Paracetamol: not as safe as we thought? A systematic literature review of obser- vational studies. Ann Rheum Dis 75:552–559. https://doi.org/10.1136/annrheumdis-2014-206914

44. Bartels EM, Bliddal H, Schondorff PK et al (2010) Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage 18:289–296. https://doi.org/10.1016/j.joca.2009.10.006

45. Towheed TE, Anastasiades T (2007) Glucosamine therapy for osteoarthritis: an update. J Rheumatol 34:1787–1790

46. Singh JA, Noorbaloooshi S, MacDonald R et al (2015) Chondroitin for osteoarthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD005614.pub2

47. Reginster JY, Bruyère O, Neuprez A (2007) Current role of glucosamine in the treatment of osteoarthritis. Rheumatology (Oxford) 46:731–735. https://doi.org/10.1093/rheumatology/kem026

48. Eriksen P, Bartels EM, Altman RD et al (2014) Risk of bias and brand explain the observed inconsistency in trials on glucosa- mine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials. Arthritis Care Res (Hoboken) 66:1844–1855. https://doi.org/10.1002/acr.22376

49. Hochberg MC (2010) Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of random- ized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage 18:828-31. https://doi.org/10.1016/j.joca.2010.02.016

50. Honvo G, Reginster JY, Rabenda V et al (2019) Safety of symptomatic slow-acting drugs for osteoarthritis: outcomes of a system- atic review and meta-analysis. Drugs Aging. 36:65–99. https://doi.org/10.1007/s40266-019-00662-z

51. Tenti S, Giordano M, Mondanelli N et al (2020) A retrospective observational study of glucosamine sulfate in addition to conven- tional therapy in hand osteoarthritis patients compared to conven- tional treatment alone. Aging Clin Exp Res 32:1161–1172. https://doi.org/10.1007/s40266-019-01305-4

52. Shin K, Kim JW, Moon KW et al (2013) The efficacy of diacerein in hand osteoarthritis: a double-blind, randomized, placebo-con- trolled study. Clin Ther 35:431–439. https://doi.org/10.1016/j.clinthera.2013.02.009

53. Arden NK, Perry TA, Bannuru RR et al (2021) Non-surgical management of knee osteoarthritis: comparison of ESCEO and...
54. Regnier JY, Veroneze N (2021) Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment. Aging Clin Exp Res 33:37–47. https://doi.org/10.1007/s40520-020-01643-8

55. Verbruggen G, Goemaere S, Veys EM (2002) Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritides drugs. Clin Rheumatol 21:231–243. https://doi.org/10.1007/s10067-002-8290-7

56. Gabay C, Medinger-Sadowski C, Gascon D et al (2011) Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center. Arthritis Rheum 63:3383–3391. https://doi.org/10.1002/art.30574

57. Honvo G, Lengelé L, Charles A et al (2020) Role of collagen derivatives in osteoarthritis and cartilage repair: a systematic scoping review with evidence mapping. Rheumatol Ther 7:703–740. https://doi.org/10.2174/2075498107666190826

58. Bartoloni E, Luccioli F, La Paglia GMC et al (2019) Effect of Sinovial High-Low® injections in trapeziometacarpal osteoarthritis. Clin Exp Rheumatol 37:166

59. Tenti S, Cheleschi S, Mondanelli N et al (2021) New trends in injection-based therapy for thumb-base osteoarthritis: where are we and where are we going? Front Pharmacol. https://doi.org/10.3389/fphar.2021.637904

60. Rocchi L, Merolli A, Giordani L et al (2017) Trapeziometacarpal joint osteoarthritis: a prospective trial on two widespread conservative therapies. Muscles Ligaments Tendons J 7:603–610. https://doi.org/10.11138/mltj/2017.7.4.603

61. Khan M, Waseem M, Raza A et al (2009) Quantitative assessment of improvement with single corticosteroid injection in thumb cmc joint osteoarthritis? Open Orthop J 3:48–51. https://doi.org/10.2174/1874325009003010048

62. Østerås N, Kjeken I, Smedslund G et al (2017) Exercise for osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 63:3389/3391. https://doi.org/10.1002/art.3389/3391

63. Biver E, Berenbaum F, Valdes AM et al (2019) Methotrexate treatment in hand osteoarthritis refractory to usual treatments: a randomized, placebo-controlled, multicentre trial. Ann Rheum Dis 78:413–420. https://doi.org/10.1136/annrheumdis-2014-205348

64. Slatkowsky-Christensen B, Mowinckel P, Kvien TK (2009) Health and where are we going? Front Pharmacol. https://doi.org/10.1136/rmdopen-2021-001660

65. Kroon FPB, Kortekaas MC, Boonen A et al (2019) Results of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial. Lancet 394:1993–2001. https://doi.org/10.1016/s0140-6736(19)32489-4

66. Park JK, Shin K, Kang EH et al (2016) Efficacy and tolerability of GCSB-5 for hand osteoarthritis: a randomized. Controlled Trial Clin Ther 38:1858-1868.e1852. https://doi.org/10.1016/j.clinthera.2016.06.016

67. Fuggle NR, Cooper C, Orefio ROC et al (2020) Alternative and complementary therapies in osteoarthritis and cartilage repair. Aging Clin Exp Res 32:547–560. https://doi.org/10.1007/s40520-020-01515-1

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
1 Nicholas Fuggle1 · Nathalie Bere2 · Olivier Bruyère3 · Mario Manuel Rosa4 · María Concepción Prieto Yerro5 · Elaine Dennison1 · Fitnat Dincer6 · Cem Gabay7 · Ida K. Haugen8 · Gabriel Herrero-Beaumont9 · Mickael Hiligsmann10 · Marc C. Hochberg11 · Andrea Laslop12 · Radmila Matijevic13,14 · Emmanuel Maheu15 · Alberto Migliore16 · Jean-Pierre Pelletier17 · Régis Pierre Radermecker18 · François Rannou19 · Brigitte Uebelhart20 · Daniel Uebelhart21 · Nicola Veronese22 · Mila Vlaskovska23 · René Rizzoli20 · Ali Mobasheri3,24,25,26,27 · Cyrus Cooper1 · Jean-Yves Reginster3

1 MRC Lifecourse Epidemiology Centre, University of Southampton, Tremona Road, Southampton SO16 6YD, UK
2 European Medicines Agency, Amsterdam, The Netherlands
3 Division of Public Health, Epidemiology and Health Economics, WHO Collaborating Center for Public Health Aspects of Musculo-Skeletal Health and Ageing, University of Liège, Avenue Hippocrate 13, CHU B23, 4000 Liège, Belgium
4 Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
5 Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain
6 Department of Physical and Rehabilitation Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey
7 Division of Rheumatology, University Hospital of Geneva, and Department of Pathology and Immunology, University of Geneva Medicine, Geneva, Switzerland
8 Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway
9 Head of Rheumatology Department, Bone and Joint Research Unit, IIS-Fundación Jiménez Díaz UAM, 28040 Madrid, Spain
10 Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, 6200 MD Maastricht, The Netherlands
11 Departments of Medicine and Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA
12 Scientific Office, Federal Office for Safety in Health Care, Vienna, Austria
13 Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
14 Clinical Center of Vojvodina, Clinic for Orthopedic Surgery, Novi Sad, Serbia
15 Rheumatology Department, Hospital Saint-Antoine, AP-HP, and Private Office, Paris, France
16 Rheumatology Unit - San Pietro Fatebenefratelli Hospital, Rome, Italy
17 Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM) and Arthritis Division, University of Montreal Hospital Centre (CHUM), Montreal, Canada
18 Department of Diabetes, Nutrition and Metabolic Disorders, Clinical Pharmacology, University of Liège, CHU de Liège, Liège, Belgium
19 Service de Rééducation et de Rénovation Node l’appareil locomoteur et des pathologies du rachis, Hôpitaux Universitaires-Paris Centre, Groupe Hospitalier Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris, INSERM U1124, Paris, France
20 Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland
21 Division of Musculoskeletal, Internal Medicine and Oncological Rehabilitation, Leukerbad Clinic - Private Rehabilitation Clinic, 3954 Leukerbad, Switzerland
22 Department of Internal Medicine, Geriatrics Section, University of Palermo, Palermo, Italy
23 Medical Faculty, Department of Pharmacology and Toxicology, Medical University Sofia, Sofia, Bulgaria
24 Research Unit of Medical Imaging, Physics and Technology, Faculty of Medicine, University of Oulu, 90014 Oulu, Finland
25 Department of Regenerative Medicine, State Research Institute Centre for Innovative Medicine, 08406 Vilnius, Lithuania
26 Departments of Orthopedics, Rheumatology and Clinical Immunology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands
27 Department of Joint Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China